NCT07618195Phase 1/2Recruiting
Study of EPI-001 in Patients With Androgenetic Alopecia
Phase I/IIa Study to Evaluate the Safety, Tolerability, and Efficacy of EPI-001 in Patients With Androgenetic Alopecia
In the register
The register attaches this trial to Epibiotech dermal papilla cell therapy (Epibiotech), currently at “Phase 1/2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 1/2
- Sponsor
- Epibiotech
- Participants (registry)
- 42
- Start
- January 2026
- Primary completion
- June 2028 (planned)
- Study completion
- June 2029 (planned)
- Last registry update
- June 2026
- Countries
- South Korea
Conditions studied: Androgenetic Alopecia
Interventions: EPI-001, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.